BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38071886)

  • 1. Compartmental Syndecan-1 (CD138) expression as a novel prognostic marker in triple-negative metaplastic breast cancer.
    Ismail Y; Zakaria AS; Allam R; Götte M; Ibrahim SA; Hassan H
    Pathol Res Pract; 2024 Jan; 253():154994. PubMed ID: 38071886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
    He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
    Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer.
    Hu J; Lang R; Zhao W; Jia Y; Tong Z; Shi Y
    Breast Cancer Res Treat; 2023 Jul; 200(1):23-36. PubMed ID: 37160814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Characteristics and Prognosis of Metaplastic Breast Cancer Compared with Invasive Ductal Carcinoma: A Propensity-Matched Analysis.
    Lee JH; Ryu JM; Lee SK; Chae BJ; Lee JE; Kim SW; Nam SJ; Yu J
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma.
    Li Y; Zhang N; Zhang H; Yang Q
    J Clin Pathol; 2019 Jun; 72(6):418-424. PubMed ID: 30872384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis.
    Qiao W; Liu H; Guo W; Li P; Deng M
    Eur J Surg Oncol; 2019 Jul; 45(7):1132-1137. PubMed ID: 30598194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of metaplastic carcinoma of the breast (MCB)--a case controlled comparison study with infiltrating ductal carcinoma.
    Lai HW; Tseng LM; Chang TW; Kuo YL; Hsieh CM; Chen ST; Kuo SJ; Su CC; Chen DR
    Breast; 2013 Oct; 22(5):968-73. PubMed ID: 23787124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy is of prognostic significance to metaplastic breast cancer.
    Zhang M; Yuan J; Wang M; Zhang M; Chen H
    Sci Rep; 2024 Jan; 14(1):1210. PubMed ID: 38216630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Syndecan-1 Immunohistochemical Expression in Lobular and Ductal Breast Carcinoma with Nodal Metastases.
    Miše I; Vučić M
    Anal Cell Pathol (Amst); 2018; 2018():9432375. PubMed ID: 30151336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of postmastectomy radiotherapy on survival outcomes of patients with metaplastic breast cancer].
    Cai W; Zhuang Y; Chen J; Wang H
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Nov; 41(11):1733-1740. PubMed ID: 34916202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological characteristics and prognosis of metaplastic breast cancer versus triple-negative invasive ductal carcinoma: a retrospective analysis.
    Yang X; Tang T; Zhou T
    World J Surg Oncol; 2023 Nov; 21(1):364. PubMed ID: 37996840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Metaplastic Breast Cancer Versus Triple-Negative Breast Cancer: A Propensity Score Matching Analysis.
    Tan Y; Yang B; Chen Y; Yan X
    World J Surg; 2023 Dec; 47(12):3192-3202. PubMed ID: 37709983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer.
    Kind S; Jaretzke A; Büscheck F; Möller K; Dum D; Höflmayer D; Hinsch A; Weidemann S; Fraune C; Möller-Koop C; Hube-Magg C; Simon R; Wilczak W; Lebok P; Witzel I; Müller V; Schmalfeldt B; Paluchowski P; Wilke C; Heilenkötter U; von Leffern I; Krech T; Krech RH; von der Assen A; Bawahab AA; Burandt E
    Mol Carcinog; 2019 Dec; 58(12):2306-2315. PubMed ID: 31545001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer.
    Jung SY; Kim HY; Nam BH; Min SY; Lee SJ; Park C; Kwon Y; Kim EA; Ko KL; Shin KH; Lee KS; Park IH; Lee S; Kim SW; Kang HS; Ro J
    Breast Cancer Res Treat; 2010 Apr; 120(3):627-37. PubMed ID: 20143153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
    Basho RK; Yam C; Gilcrease M; Murthy RK; Helgason T; Karp DD; Meric-Bernstam F; Hess KR; Valero V; Albarracin C; Litton JK; Chavez-MacGregor M; Hong D; Kurzrock R; Hortobagyi GN; Janku F; Moulder SL
    Oncologist; 2018 Nov; 23(11):1300-1309. PubMed ID: 30139837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes.
    McQuerry JA; Jenkins DF; Yost SE; Zhang Y; Schmolze D; Johnson WE; Yuan Y; Bild AH
    BMC Cancer; 2019 Sep; 19(1):881. PubMed ID: 31488082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of RSPO1, WNT1, P16, WT1, and SDC1 expressions in invasive ductal carcinoma of the breast.
    Choi EJ; Yun JA; Jeon EK; Won HS; Ko YH; Kim SY
    World J Surg Oncol; 2013 Dec; 11():314. PubMed ID: 24373193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma.
    Li JP; Zhang XM; Zhang Z; Zheng LH; Jindal S; Liu YJ
    Medicine (Baltimore); 2019 May; 98(18):e15449. PubMed ID: 31045815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.
    Hartog H; Horlings HM; van der Vegt B; Kreike B; Ajouaou A; van de Vijver MJ; Marike Boezen H; de Bock GH; van der Graaf WT; Wesseling J
    Breast Cancer Res Treat; 2011 Oct; 129(3):725-36. PubMed ID: 21107683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ.
    Liu Y; Yu T
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11181-11191. PubMed ID: 37354223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.